CRSHIGH SIGNALFINANCIAL10-K

CRS delivered exceptionally strong financial performance with revenue growing 20% and operating income substantially higher year-over-year, while significantly strengthening its balance sheet position.

The company's operating leverage is clearly evident as revenue growth of 20% translated into meaningfully expanded operating income, suggesting improved operational efficiency and margin expansion. The substantial increase in operating cash flow to $440.4M and cash position rising to $315.5M demonstrates strong cash generation capabilities and enhanced financial flexibility for future investments or shareholder returns.

Comparing 2025-08-12 vs 2024-08-13View on EDGAR →
FINANCIAL ANALYSIS

CRS posted strong across-the-board financial improvements with revenue reaching $2.2B and gross profit expanding to $768.6M, reflecting solid demand and pricing power. Operating performance was particularly impressive with substantially higher operating income despite modestly increased interest expense of $54.1M. The balance sheet strengthened considerably with cash and equivalents growing to $315.5M and stockholders equity expanding to $1.9B, indicating robust cash generation and improved financial position.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+61.5%
$323.1M$521.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+60.2%
$274.9M$440.4M

Operating cash flow surged 60.2% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
+58.5%
$199.1M$315.5M

Cash position surged 58.5% — strong cash generation or capital raise providing significant financial cushion.

Gross Profit
P&L
+31.5%
$584.3M$768.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Interest Expense
P&L
+20.5%
$44.9M$54.1M

Interest costs rose 20.5% — monitor debt levels and coverage ratio in rising rate environment.

Revenue
P&L
+20%
$1.8B$2.2B

Revenue growing 20% — solid top-line momentum, watch margins for quality of growth.

Stockholders Equity
Balance Sheet
+15.9%
$1.6B$1.9B

Equity base grew 15.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+10.9%
$1.6B$1.8B

Current assets grew 10.9% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2025-08-12
PRIOR — 2024-08-13
ADDED
As of August 8, 2025, 49,850,095 shares of the registrant's common stock were outstanding.
Purchase prices of certain raw materials have historically been volatile, including the impact of tariffs.
(6) Competition: We are leaders in specialty materials for critical applications with over 135 years of metallurgical and manufacturing expertise.
(7) Research, Product and Process Development: Our expenditures for Company-sponsored research and development were $26.1 million, $25.6 million and $24.4 million in fiscal years 2025 , 2024 and 2023 , respectively.
The capital expenditures for environmental control equipment were $1.1 million, $0.7 million and $0.3 million for fiscal years 2025, 2024 and 2023, respectively.
+7 more — sign up free →
REMOVED
As of August 9, 2024, 49,947,498 shares of the registrant's common stock were outstanding.
Purchase prices of certain raw materials have historically been volatile.
(6) Backlog: As of June 30, 2024 , we had a sales backlog of orders excluding surcharge, believed to be firm, of approximately $2,256.6 million, significantly all of which is expected to be shipped within fiscal years 2025 and 2026.
Our backlog of orders excluding surcharge as of June 30, 2023, was approximately $2,123.3 million.
(7) Competition: We are leaders in specialty materials for critical applications with over 130 years of metallurgical and manufacturing expertise.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →